1
|
Valentino M, Dejana E, Malinverno M. The multifaceted PDCD10/CCM3 gene. Genes Dis 2021; 8:798-813. [PMID: 34522709 PMCID: PMC8427250 DOI: 10.1016/j.gendis.2020.12.008] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2020] [Revised: 12/10/2020] [Accepted: 12/22/2020] [Indexed: 02/06/2023] Open
Abstract
The programmed cell death 10 (PDCD10) gene was originally identified as an apoptosis-related gene, although it is now usually known as CCM3, as the third causative gene of cerebral cavernous malformation (CCM). CCM is a neurovascular disease that is characterized by vascular malformations and is associated with headaches, seizures, focal neurological deficits, and cerebral hemorrhage. The PDCD10/CCM3 protein has multiple subcellular localizations and interacts with several multi-protein complexes and signaling pathways. Thus PDCD10/CCM3 governs many cellular functions, which include cell-to-cell junctions and cytoskeleton organization, cell proliferation and apoptosis, and exocytosis and angiogenesis. Given its central role in the maintenance of homeostasis of the cell, dysregulation of PDCD10/CCM3 can result in a wide range of altered cell functions. This can lead to severe diseases, including CCM, cognitive disability, and several types of cancers. Here, we review the multifaceted roles of PDCD10/CCM3 in physiology and pathology, with a focus on its functions beyond CCM.
Collapse
Affiliation(s)
| | - Elisabetta Dejana
- The FIRC Institute of Molecular Oncology (IFOM), Milan, 16 20139, Italy.,Department of Oncology and Haemato-Oncology, University of Milan, Milan, 7 20122, Italy.,Vascular Biology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SE-751 05, Sweden
| | - Matteo Malinverno
- The FIRC Institute of Molecular Oncology (IFOM), Milan, 16 20139, Italy
| |
Collapse
|
2
|
De Marco C, Zoppoli P, Rinaldo N, Morganella S, Morello M, Zuccalà V, Carriero MV, Malanga D, Chirillo R, Bruni P, Malzoni C, Di Vizio D, Venturella R, Zullo F, Rizzuto A, Ceccarelli M, Ciliberto G, Viglietto G. Genome-wide analysis of copy number alterations led to the characterisation of PDCD10 as oncogene in ovarian cancer. Transl Oncol 2021; 14:101013. [PMID: 33516089 PMCID: PMC7846933 DOI: 10.1016/j.tranon.2021.101013] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2020] [Revised: 12/04/2020] [Accepted: 01/04/2021] [Indexed: 12/13/2022] Open
Abstract
We have identified 201 altered chromosomal bands and 3300 altered genes in human ovarian cancer samples. The gene encoding for PDCD10 was selected for further studies. PDCD10 was found to be over-expressed in primary cancer samples and in the corresponding metastatic lesions. High PDCD10 expression correlates with grade, nodal involvement or advanced FIGO stage. PDCD10 is involved in the control of cell growth and motility in vitro as well as tumorigenicity in vivo.
Copy Number Alterations (CNAs) represent the most common genetic alterations identified in ovarian cancer cells, being responsible for the extensive genomic instability observed in this cancer. Here we report the identification of CNAs in a cohort of Italian patients affected by ovarian cancer performed by SNP-based array. Our analysis allowed the identification of 201 significantly altered chromosomal bands (70 copy number gains; 131 copy number losses). The 3300 genes subjected to CNA identified here were compared to those present in the TCGA dataset. The analysis allowed the identification of 11 genes with increased CN and mRNA expression (PDCD10, EBAG9, NUDCD1, ENY2, CSNK2A1, TBC1D20, ZCCHC3, STARD3, C19orf12, POP4, UQCRFS1). PDCD10 was selected for further studies because of the highest frequency of CNA. PDCD10 was found, by immunostaining of three different Tissue Micro Arrays, to be over-expressed in the majority of ovarian primary cancer samples and in metastatic lesions. Moreover, significant correlations were found in specific subsets of patients, between increased PDCD10 expression and grade (p < 0.005), nodal involvement (p < 0.05) or advanced FIGO stage (p < 0.01). Finally, manipulation of PDCD10 expression by shRNA in ovarian cancer cells (OVCAR-5 and OVCA429) demonstrated a positive role for PDCD10 in the control of cell growth and motility in vitro and tumorigenicity in vivo. In conclusion, this study allowed the identification of novel genes subjected to copy number alterations in ovarian cancer. In particular, the results reported here point to a prominent role of PDCD10 as a bona fide oncogene.
Collapse
Affiliation(s)
- Carmela De Marco
- Department of Experimental and Clinical Medicine, "Magna Graecia", University Catanzaro, Italy.
| | - Pietro Zoppoli
- Department of Experimental and Clinical Medicine, "Magna Graecia", University Catanzaro, Italy
| | - Nicola Rinaldo
- Biogem Scarl, Institute for Genetic Research "G. Salvatore", Ariano Irpino (AV), Italy
| | - Sandro Morganella
- Biogem Scarl, Institute for Genetic Research "G. Salvatore", Ariano Irpino (AV), Italy
| | - Matteo Morello
- Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles (CA), USA
| | - Valeria Zuccalà
- Pathology Unit, "Pugliese-Ciaccio" Hospital, Catanzaro, Italy
| | | | - Donatella Malanga
- Department of Experimental and Clinical Medicine, "Magna Graecia", University Catanzaro, Italy
| | - Roberta Chirillo
- Department of Experimental and Clinical Medicine, "Magna Graecia", University Catanzaro, Italy
| | - Paola Bruni
- Casa di Cura "Malzoni-Villa dei Platani", Avellino, Italy
| | | | - Dolores Di Vizio
- Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles (CA), USA
| | - Roberta Venturella
- Unit of Obstetrics and Gynaecology, "Magna Graecia" University of Catanzaro, Italy
| | - Fulvio Zullo
- Unit of Obstetrics and Gynaecology, "Magna Graecia" University of Catanzaro, Italy
| | - Antonia Rizzuto
- Department of Medical and Surgical Sciences, "Magna Graecia", Catanzaro, Italy
| | - Michele Ceccarelli
- Biogem Scarl, Institute for Genetic Research "G. Salvatore", Ariano Irpino (AV), Italy
| | | | - Giuseppe Viglietto
- Department of Experimental and Clinical Medicine, "Magna Graecia", University Catanzaro, Italy.
| |
Collapse
|
3
|
Dwivedi R, Pandey R, Chandra S, Mehrotra D. Apoptosis and genes involved in oral cancer - a comprehensive review. Oncol Rev 2020; 14:472. [PMID: 32685111 PMCID: PMC7365992 DOI: 10.4081/oncol.2020.472] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2019] [Accepted: 03/20/2020] [Indexed: 12/24/2022] Open
Abstract
Oral cancers needs relentless research due to high mortality and morbidity associated with it. Despite of the comparable ease in accessibility to these sites, more than 2/3rd cases are diagnosed in advanced stages. Molecular/genetic studies augment clinical assessment, classification and prediction of malignant potential of oral lesions, thereby reducing its incidence and increasing the scope for early diagnosis and treatment of oral cancers. Herein we aim to review the role of apoptosis and genes associated with it in oral cancer development in order to aid in early diagnosis, prediction of malignant potential and evaluation of possible treatment targets in oral cancer. An internet-based search was done with key words apoptosis, genes, mutations, targets and analysis to extract 72 articles after considering inclusion and exclusion criteria. The knowledge of genetics and genomics of oral cancer is of utmost need in order to stop the rising prevalence of oral cancer. Translational approach and interventions at the early stage of oral cancer, targeted destruction of cancerous cells by silencing or promoting involved genes should be the ideal intervention.
Collapse
Affiliation(s)
- Ruby Dwivedi
- DHR-MRU & Department of Oral and Maxillofacial Surgery, Faculty of Dental Sciences, King George's Medical University, Lucknow, Uttar Pradesh, India
| | - Rahul Pandey
- DHR-MRU & Department of Oral and Maxillofacial Surgery, Faculty of Dental Sciences, King George's Medical University, Lucknow, Uttar Pradesh, India
| | - Shaleen Chandra
- DHR-MRU & Department of Oral and Maxillofacial Surgery, Faculty of Dental Sciences, King George's Medical University, Lucknow, Uttar Pradesh, India
| | - Divya Mehrotra
- DHR-MRU & Department of Oral and Maxillofacial Surgery, Faculty of Dental Sciences, King George's Medical University, Lucknow, Uttar Pradesh, India
| |
Collapse
|
4
|
Ryuno H, Naguro I, Kamiyama M. ASK family and cancer. Adv Biol Regul 2017; 66:72-84. [PMID: 28552579 DOI: 10.1016/j.jbior.2017.05.003] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2017] [Revised: 05/17/2017] [Accepted: 05/17/2017] [Indexed: 06/07/2023]
Abstract
Cancer is a major problem in public health and is one of the leading causes of mortality worldwide. Many types of cancer cells exhibit aberrant cellular signal transduction in response to stress, which often leads to oncogenesis. Mitogen-activated protein kinase (MAPK) signal cascades are one of the important intracellular stress signaling pathways closely related to cancer. The key molecules in MAPK signal cascades that respond to various types of stressors are apoptosis signal-regulating kinase (ASK) family members; ASK1, ASK2 and ASK3. ASK family members are activated by a wide variety of stressors, and they regulate various cellular responses, such as cell proliferation, inflammation and apoptosis. In this review, we will discuss both the oncogenic and anti-oncogenic roles of the ASK family members in various contexts of cancer development with deeper insights into the involvement of ASK family members in cancer pathology.
Collapse
Affiliation(s)
- Hiroki Ryuno
- Laboratory of Cell Signaling, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Isao Naguro
- Laboratory of Cell Signaling, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Miki Kamiyama
- Laboratory of Cell Signaling, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
| |
Collapse
|
5
|
Fu X, Zhang W, Su Y, Lu L, Wang D, Wang H. MicroRNA-103 suppresses tumor cell proliferation by targeting PDCD10 in prostate cancer. Prostate 2016; 76:543-51. [PMID: 26771762 DOI: 10.1002/pros.23143] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/09/2015] [Accepted: 12/15/2015] [Indexed: 12/29/2022]
Abstract
BACKGROUND It is known that microRNAs (miRNAs) are a class of small, non-coding RNAs that act as key regulators in various physiological and pathological processes. However, the regulatory mechanisms involving miRNAs in prostate cancer remain largely unknown. Here, we found that miR-103 is down-regulated in prostate cancer and closely associated with tumor proliferation and migration. Our objective was to explore the role of the miR-103 in prostate cancer. METHODS In this study, we measured miR-103 level using real-time polymerase chain reaction in the human prostate cancer cell lines, including PC-3, LNCap, 22Rv1, DU145, and the normal prostate epithelium cell line RWPE-1, a total of 25 pairs of primary prostate cancer tissues and adjacent non-cancerous tissues (NCTs) were measured also. In addition, over-expression of miR-103 in prostate cancer cell lines to determine the role of miR-103 in prostate cancer. RESULTS We found that miR-103 is down-regulated in prostate cancer and closely associated with tumor proliferation and migration. In addition, over-expression of miR-103 apparently inhibits prostate cancer cell proliferation and migration in vitro. Gain-of-function in vitro experiments further show that miR-103 mimics significantly inhibited prostate cancer cell proliferation, invasion and increase the cell cycle in G1 phase, while promoted cell apoptosis. Subsequent dual-luciferase reporter assay identified one of the proto-oncogene PDCD10 as direct target of miR-103. CONCLUSIONS Therefore, our data collectively demonstrate that miR-103 is a proto-oncogene miRNA that can suppress prostate cancer proliferation and migration by down-regulating the oncogene PDCD10, indicating that miR-103 may represent a new potential diagnostic and therapeutic target for prostate cancer treatment.
Collapse
Affiliation(s)
- Xiaoliang Fu
- Departmentof Urology, Xi'an Tangdu Hospital, The Fourth Military Medical University, Xi'an, China
| | - Wei Zhang
- Departmentof Urology, Xi'an Tangdu Hospital, The Fourth Military Medical University, Xi'an, China
| | - Yansheng Su
- The Chinese People's Liberation Army 323 hospital, Xi'an, China
| | - Lu Lu
- Armed Police Hospital of Shaanxi, Xi'an, China
| | - Dong Wang
- Departmentof Urology, Xi'an Tangdu Hospital, The Fourth Military Medical University, Xi'an, China
| | - He Wang
- Departmentof Urology, Xi'an Tangdu Hospital, The Fourth Military Medical University, Xi'an, China
| |
Collapse
|
6
|
Li S, Chai L, Cai Z, Jin L, Chen Y, Wu H, Sun Z. Expression of Survivin and Caspase 3 in Oral Squamous Cell Carcinoma and Peritumoral Tissue. Asian Pac J Cancer Prev 2012; 13:5027-31. [DOI: 10.7314/apjcp.2012.13.10.5027] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
7
|
Li F, Jiang Z, Wang K, Guo J, Hu G, Sun L, Wang T, Tang X, He L, Yao J, Wen D, Qin X, Zhang L. Transactivation of the human NME5 gene by Sp1 in pancreatic cancer cells. Gene 2012; 503:200-7. [DOI: 10.1016/j.gene.2012.04.088] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2012] [Revised: 03/19/2012] [Accepted: 04/28/2012] [Indexed: 10/28/2022]
|
8
|
Li F, Hu G, Jiang Z, Guo J, Wang K, Ouyang K, Wen D, Zhu M, Liang J, Qin X, Zhang L. Identification of NME5 as a contributor to innate resistance to gemcitabine in pancreatic cancer cells. FEBS J 2012; 279:1261-73. [PMID: 22325559 DOI: 10.1111/j.1742-4658.2012.08521.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
The limited therapeutic effect of gemcitabine on pancreatic cancer is largely attributed to pre-existing or acquired resistance of the tumor cells. This study was aimed at screening for candidate resistance-related gene(s) and elucidating the underlying mechanisms. NME5 was found to be highly expressed in an innate gemcitabine-resistant human pancreatic cancer sample and the cell line PAXC002 derived from the sample. Downregulation of NME5 significantly reversed gemcitabine resistance in PAXC002 cells, whereas NME5 overexpression induced gemcitabine resistance in the pancreatic cancer cell line BxPC-3. NME5 attenuated the induction of apoptosis and cell cycle arrest induced by gemcitabine, probably accounting for the blunted sensitivity to gemcitabine. Furthermore, NME5 was demonstrated to play its role in a nuclear factor kappaB (NF-κB)-dependent manner. NME5 was capable of directly binding NF-κB, and possibly regulated its expression level in PAXC002 cells. Our results also suggest that NF-κB is a key executor of NME5 in regulating apoptosis and cell cycle. All of these data suggest that NME5 is a promising target for relieving innate gemcitabine resistance in pancreatic cancer cells.
Collapse
Affiliation(s)
- Fu Li
- Jiangsu Center of Drug Screening, China Pharmaceutical University, Nanjing, Jiangsu Province, China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Villarroel Dorrego M, Speight PM, Barrett AW. CD40 in human oral epithelia. Oral Oncol 2007; 43:626-33. [PMID: 17307023 DOI: 10.1016/j.oraloncology.2006.12.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2006] [Revised: 11/30/2006] [Accepted: 12/01/2006] [Indexed: 02/04/2023]
Abstract
CD40 is a transmembrane glycoprotein belonging to the tumour necrosis factor receptor superfamily, which has a role in a number of biological functions, including the regulation of cell growth and division, and cell mediated immunity. Although originally described on leucocytes, principally B lymphocytes, there is now abundant evidence for the cellular diversity of CD40. The aim of this article is to review the available data on CD40 in oral epithelium, principally that lining the oral mucosa, but also that of the salivary glands.
Collapse
Affiliation(s)
- Mariana Villarroel Dorrego
- Department of Oral Pathology, Oral Medicine and Oral Surgery, Universidad Santa Maria and Institute of Dental Research, Universidad Central de Venezuela, Caracas, Venezuela
| | | | | |
Collapse
|